The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer

2008 ◽  
Vol 12 (3) ◽  
pp. 233-243 ◽  
Author(s):  
Emma Pennery
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Hormone Receptor ◽  
Risk Of Recurrence ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

scholarly journals Association Between Age at Diagnosis and Disease-Specific Mortality Among Postmenopausal Women With Hormone Receptor–Positive Breast Cancer

JAMA ◽  
2012 ◽  
Vol 307 (6) ◽  
Author(s):  
Willemien van de Water ◽  
Christos Markopoulos ◽  
Cornelis J. H. van de Velde ◽  
Caroline Seynaeve ◽  
Annette Hasenburg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Hormone Receptor ◽  
Age At Diagnosis ◽  
Hormone Receptor Positive ◽  
Specific Mortality ◽  
Disease Specific Mortality ◽  
Disease Specific ◽  
Positive Breast Cancer

scholarly journals Aromatase Inhibitor-Associated Tendinopathy and Muscle Tendon Rupture: Report of Three Cases of This Exceedingly Rare Adverse Event

2018 ◽  
Vol 11 (2) ◽  
pp. 557-561 ◽  
Author(s):  
Nikolaos Mitsimponas ◽  
Evangelia Klouva ◽  
Dimitrios Tryfonopoulos ◽  
Anastasios Grivas ◽  
Stamatina Demiri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Hormone Receptor ◽  
Tendon Rupture ◽  
Medical Literature ◽  
Systemic Disease ◽  
Hormone Receptor Positive ◽  
Antihormonal Treatment ◽  
Antihormonal Therapy ◽  
Positive Breast Cancer

Aromatase inhibitors (AIs) are a commonly used antihormonal therapy in the treatment of breast cancer in postmenopausal women, specifically in the treatment of hormone receptor-positive breast cancer. AI-associated tendinopathy and muscle tendon rupture is exceedingly rare. Until now, only one case with AI-associated severe tendinopathy has been reported in the medical literature, and there are no recorded cases of AI-associated muscle tendon rapture. We report three cases of postmenopausal women with hormone receptor-positive breast cancer, who experienced tendinopathy or muscle tendon rupture under antihormonal treatment with letrozole. All of the three women were in the adjuvant setting, and the treatment of tendinopathy or tendon rupture consisted of AI discontinuation, initiation of corticosteroids, or surgical treatment. Diagnosis was made via MRI. Furthermore, in our cases, there were no signs of underlying systemic disease, there was no abnormal physical activity preceding the complaints, and there was no use of other drugs beside letrozole. AIs are one of the most commonly used drugs in antihormonal therapy for hormone receptor-positive breast cancer. In every case of a female patient with hormone receptor-positive breast cancer under treatment with AIs and arthralgia, an MRI should be performed in order to exclude the presence of tendinopathy or muscle tendon rupture.

Sign in / Sign up

Export Citation Format

Share Document